These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28823077)

  • 1. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.
    Hattori Y; Kida D; Kaneko A
    Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
    Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
    Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.
    Hirano F; Yokoyama W; Yamazaki H; Amano K; Kawakami A; Hayashi T; Tamura N; Yasuda S; Dobashi H; Fujii T; Ito S; Kaneko Y; Matsui T; Okuda Y; Saito K; Suzuki F; Yoshimi R; Sakai R; Koike R; Kohsaka H; Miyasaka N; Harigai M;
    Mod Rheumatol; 2017 Sep; 27(5):811-819. PubMed ID: 27919205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
    Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
    Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
    Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
    J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.
    Radner H; Alasti F; Smolen JS; Aletaha D
    Arthritis Res Ther; 2015 Aug; 17(1):203. PubMed ID: 26259838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
    Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.
    Tanaka Y; Yamanaka H; Saito K; Iwata S; Miyagawa I; Seto Y; Momohara S; Nagasawa H; Kameda H; Kaneko Y; Izumi K; Amano K; Takeuchi T
    Mod Rheumatol; 2012 Apr; 22(2):186-94. PubMed ID: 21901357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
    Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
    Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.
    Yamazaki H; Hirano F; Takeuchi T; Amano K; Kikuchi J; Kihara M; Yokoyama W; Sugihara T; Nagasaka K; Hagiyama H; Nonomura Y; Sakai R; Tanaka M; Koike R; Nanki T; Kohsaka H; Miyasaka N; Harigai M
    Mod Rheumatol; 2017 Sep; 27(5):787-794. PubMed ID: 27846756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
    Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
    J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study.
    de Andrade NPB; da Silva Chakr RM; Xavier RM; Viecceli D; Correa RHB; de Oliveira Filho CM; Brenol CV
    Rheumatol Int; 2017 Jun; 37(6):993-997. PubMed ID: 28293776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry.
    Guo N; Li X; Movahedi M; Cesta A; Bombardier C
    Clin Exp Rheumatol; 2024 May; 42(5):1067-1074. PubMed ID: 38372710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2024 Jul; 26(1):140. PubMed ID: 39061106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.